Novartis AG (NVS)
| Market Cap | 266.66B +4.6% |
| Revenue (ttm) | 56.69B +2.7% |
| Net Income | 12.76B -6.6% |
| EPS | 6.61 -3.4% |
| Shares Out | 1.90B |
| PE Ratio | 20.90 |
| Forward PE | 15.03 |
| Dividend | $3.08 (2.19%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 2,246,668 |
| Open | 141.46 |
| Previous Close | 141.05 |
| Day's Range | 139.95 - 141.57 |
| 52-Week Range | 121.57 - 170.46 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 156.29 (+10.84%) |
| Earnings Date | Oct 27, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $156.29, which is an increase of 10.84% from the latest price.
News
Novartis Signs Deal With Abogen For MRNA Therapies
(RTTNews) - Swiss pharmaceutical company Novartis AG (NVS) announced it has entered into a licensing and option agreement with China-based Abogen Biosciences to develop mRNA-encoded therapies, includi...
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billion. It comes after several pharma peers announced deals with China-based drug developers over the pas...
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
Abogen said its lead drug has potential to transform the treatment landscape for patients with autoimmune diseases.
Novartis (NVS) Secures $575M Licensing Deal with Abogen Biosciences for Innovative mRNA Therapy
Novartis (NVS) Secures $575M Licensing Deal with Abogen Biosciences for Innovative mRNA Therapy
Novartis signs mRNA deal for about $7.8 billion with China's Abogen
Chinese biotech company Abogen said on Friday it signed a licensing deal worth about $7.8 billion with Swiss drug maker Novartis to advance RNA-based therapy.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Dan...
Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors
Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such investors are advised to contac...
Novartis defeats drug-purchaser lawsuit over delay of Entresto generics
A federal judge in Manhattan ruled for Novartis on Wednesday against allegations that it misused one of its patents to maintain its exclusivity on its blockbuster heart-failure drug Entresto.
European drugmakers call for faster trials, more spending to compete with US, China
European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings on Tuesday that the continent's pharmaceutical industry risks los...
BoomRay Pharma, Novartis Ink Radioligand Therapy Licensing Deal Worth Up To $900 Mln
(RTTNews) - BoomRay Pharmaceuticals Co., Ltd., a clinical-stage biotechnology company, announced an exclusive global license agreement with Novartis Pharma AG (NVS) for an undisclosed preclinical radi...
Novartis' Pipeline In Focus After A Series Of Clinical Setbacks
(RTTNews) - Novartis has come under increasing pressure after a series of clinical and pipeline setbacks in the second half of 2026, culminating in calls from a major shareholder for changes to the co...
Novartis announces positive CHMP opinion for Cosentyx
Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Cosentyx in po...
Novartis Halts Development Of VHB937 After ASTRALS Phase 2 Trial Fails To Meet Endpoint
(RTTNews) - Novartis (NVS) announced on August 25, 2026, that its ASTRALS Phase 2 clinical trial evaluating VHB937 for amyotrophic lateral sclerosis did not meet its primary or secondary endpoints, le...
Novartis halts ALS drug development after mid-stage trial failure
Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals in a mid-stage study, marking the latest disappointment for the Swiss drugmake...
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares
Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.
Legend Biotech taps Novartis veteran Zhang as CEO
Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy ...
Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July
Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
CBSE Primary Teachers Tier 2 Result Out For KVS, NVS: Check Next Steps
CBSE Teacher Recruitment: Candidates are advised to regularly visit the official websites of CBSE, KVS and NVS and their application login for further updates.
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Novartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen. Lilly is also developing a therapy for lowering Lp(a).
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Novartis: More Pain on the Way?
The bad diagnoses just keep on coming for the Swiss drugmaker.
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Novartis investors to increase scrutiny of company’s strategy, Reuters reports
Novartis (NVS) investors will be increasing their scrutiny of the company’s dealmaking strategy following setbacks to drugs acquired through mergers and acquisitions, Bhanvi Satija, Oliver Hirt and Ma...